Clinical trial
Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1
NCT00089570 · Mallinckrodt, Industry · Completed
Key facts
| NCT number | NCT00089570 |
|---|---|
| Title | Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1 |
| Official title | A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III Study of Intravenous Terlipressin in Patients With Hepatorenal Syndrome Type 1 |
| Lead sponsor | Mallinckrodt, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatorenal Syndrome |
| Intervention type | Drug |
| Interventions | terlipressin, Placebo |
| Enrollment | 112 |
| Start date | Jun 1, 2004 |
| Primary completion | Mar 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Aug 9, 2004 |
| Last update posted | Oct 27, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: